celecoxib and Kidney Diseases studies

Research Excerpts

Excerpt	Relevance	Reference
"Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen."	9.22	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016)
"We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily."	9.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
"The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose."	9.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)."	5.27	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018)
"Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen."	5.22	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016)
"We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily."	5.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
"The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose."	5.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
" Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development."	4.81	[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001)
"Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis."	4.80	Celecoxib clinical profile. ( Tive, L, 2000)
" Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy."	2.41	Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002)
" CDDP-induced nephrotoxicity (CIN) is one of the most severe adverse events associated with the use of CDDP."	1.56	Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. ( Furugen, A; Iseki, K; Kobayashi, M; Narumi, K; Okamoto, K; Saito, Y, 2020)
"To perform an international comparison and analysis of celecoxib spontaneous adverse event reports (AERs) from Canada, Australia and the United States, focusing on gastrointestinal, renal and cardiovascular events."	1.51	Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. ( Ahmed, R; Baselyous, Y; De Cocinis, M; Ibrahim, M; Kalra, A; Yacoub, R, 2019)
"Celecoxib (40 mg/kg) was co-administered once daily to one vehicle and one misoprostol group from days 3 to 9."	1.40	Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats. ( Bullins, KW; Campbell, GE; Conder, CM; Cooper, DL; Denham, JW; Hanley, AV; Harirforoosh, S; Lynch, SP; Murrell, DE; Palau, VE; Panus, PC; Singh, K, 2014)
"Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is primarily limited by renal and gastrointestinal adverse effects."	1.39	Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats. ( Bullins, KW; Denham, JW; Hanley, AV; Hanley, GA; Harirforoosh, S; Panus, PC; Wood, RC; Wyatt, JE, 2013)
" Randomized clinical trials had demonstrated fewer adverse gastrointestinal events with COX-2 inhibitors, but no difference with other adverse events, including adverse renal events."	1.35	NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. ( Gilbert, AL; Pratt, N; Ramsay, E; Roughead, EE, 2008)
"Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors."	1.31	[Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001)

Research

Studies (28)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	19 (67.86)	29.6817
2010's	7 (25.00)	24.3611
2020's	2 (7.14)	2.80

Authors	Studies
Abdelrahman, RS	1
Abdelmageed, ME	1
Okamoto, K	1
Saito, Y	1
Narumi, K	1
Furugen, A	1
Iseki, K	1
Kobayashi, M	1
Solomon, DH	2
Husni, ME	2
Wolski, KE	2
Wisniewski, LM	2
Borer, JS	2
Graham, DY	2
Libby, P	2
Lincoff, AM	2
Lüscher, TF	2
Menon, V	2
Yeomans, ND	2
Wang, Q	2
Bao, W	2
Berger, MF	2
Nissen, SE	2
Baselyous, Y	1
De Cocinis, M	1
Ibrahim, M	1
Kalra, A	1
Yacoub, R	1
Ahmed, R	1
Wood, RC	1
Wyatt, JE	1
Bullins, KW	2
Hanley, AV	2
Hanley, GA	1
Denham, JW	2
Panus, PC	2
Harirforoosh, S	2
El-Gowelli, HM	1
Helmy, MW	1
Ali, RM	1
El-Mas, MM	1
Cooper, DL	1
Murrell, DE	1
Conder, CM	1
Palau, VE	1
Campbell, GE	1
Lynch, SP	1
Singh, K	1
Farag, MM	1
Khalifa, AA	1
Elhadidy, WF	1
Rashad, RM	1
Ruschitzka, F	1
Gaffney, M	1
Beckerman, B	1
Roughead, EE	1
Ramsay, E	1
Pratt, N	1
Gilbert, AL	1
Phillips, E	1
Hinck, B	1
Pedro, R	1
Makhlouf, A	1
Kriedberg, C	1
Hendlin, K	1
Monga, M	1
LeLorier, J	1
Bombardier, C	1
Burgess, E	1
Moist, L	1
Wright, N	1
Cartier, P	1
Huckell, V	1
Hunt, R	1
Nawar, T	1
Tobe, S	1
Bing, RJ	1
Harley, C	1
Wagner, S	1
Nurmohamed, MT	1
Lems, WF	1
Verrico, MM	1
Weber, RJ	1
McKaveney, TP	1
Ansani, NT	1
Towers, AL	1
Fujihara, CK	1
Antunes, GR	1
Mattar, AL	1
Andreoli, N	1
Malheiros, DM	1
Noronha, IL	1
Zatz, R	1
White, WB	1
Campbell, MS	1
Makar, GA	1
Clifford, TM	1
Pajoumand, M	1
Johnston, TD	1
Mathieu, C	1
Meier, P	1
Meyer zu Starten, A	1
Burnier, M	1
Bertagnolli, MM	1
Eagle, CJ	2
Zauber, AG	2
Redston, M	1
Solomon, SD	2
Kim, K	1
Tang, J	2
Rosenstein, RB	2
Wittes, J	2
Corle, D	1
Hess, TM	1
Woloj, GM	1
Boisserie, F	1
Anderson, WF	1
Viner, JL	1
Bagheri, D	1
Burn, J	1
Chung, DC	1
Dewar, T	1
Foley, TR	1
Hoffman, N	1
Macrae, F	1
Pruitt, RE	1
Saltzman, JR	1
Salzberg, B	1
Sylwestrowicz, T	1
Gordon, GB	1
Hawk, ET	1
Arber, N	1
Spicak, J	1
Rácz, I	1
Dite, P	1
Hajer, J	1
Zavoral, M	1
Lechuga, MJ	1
Gerletti, P	1
Macdonald, K	1
Bhadra, P	1
Fowler, R	1
Levin, B	1
Tabibian, JH	1
Tabibian, N	1
Kaufman, DM	1
Tive, L	1
Nakamura, H	1
Deray, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216]	Phase 4	24,081 participants (Actual)	Interventional	2006-10-04	Completed
Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812]	Phase 4	100 participants (Anticipated)	Interventional	2021-04-22	Recruiting
Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088]		75 participants (Actual)	Interventional	2019-05-02	Completed
Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094]	Phase 3	1,170 participants (Anticipated)	Interventional	2000-03-31	Completed
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614]	Phase 2	58 participants (Actual)	Interventional	2003-03-31	Completed
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193]	Phase 3	1,561 participants (Actual)	Interventional	2001-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months

The First Occurrence of a Major Adverse Cardiovascular Events (MACE)

Intervention	Number of participants (Mean)
	Baseline (ITT) N= 8014, 8001, 7928	Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325	Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149	Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740	Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159	Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846	Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246	Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785	Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086	Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635	Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439	Baseline (MITT) N=7974, 7954, 7894	Change-Baseline to Mon1 MITT N=7372, 7367, 7321	Change-Baseline to Mon2 MITT N=7170, 7078, 7142	Change-Baseline to Mon4 MITT N=6772, 6686, 6732	Change-Baseline to Mon8 MITT N=6224, 6128, 6155	Change-Baseline to Mon12 MITT N=5787, 5689, 5844	Change-Baseline to Mon18 MITT N=5305, 5175, 5242	Change-Baseline to Mon24 MITT N=4815, 4769, 4782	Change-Baseline to Mon30 MITT N=4139, 4067, 4085	Change-Baseline to Mon36 MITT N=3691, 3623, 3635	Change-Baseline to Mon42 MITT N=3468, 3404, 3438
Celecoxib	54.0	-8.2	-10.5	-11.4	-11.7	-11.0	-11.3	-11.3	-10.5	-10.1	-11.4	54.0	-8.2	-10.5	-11.4	-11.7	-11.0	-11.3	-11.4	-10.5	-10.2	-11.4
Ibuprofen	54.1	-9.0	-10.6	-11.7	-12.1	-11.6	-11.3	-11.5	-11.2	-10.7	-11.1	54.1	-9.0	-10.6	-11.7	-12.1	-11.6	-11.3	-11.5	-11.2	-10.7	-11.1
Naproxen	54.1	-9.9	-11.1	-12.3	-12.1	-11.9	-11.7	-11.4	-11.3	-11.6	-12.1	54.1	-9.9	-11.1	-12.3	-12.1	-11.9	-11.7	-11.3	-11.3	-11.6	-12.1

MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

Intervention	Percentage of Participants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	4.2	3.1
Ibuprofen	4.8	3.6
Naproxen	4.3	3.2

APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months

The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

Intervention	Percentage of Partcipants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	2.3	1.7
Ibuprofen	2.7	1.9
Naproxen	2.5	1.8

CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

Article	Year
Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. The Canadian journal of cardiology, 2002, Volume: 18, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Gl	2002
Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events? Current atherosclerosis reports, 2003, Volume: 5, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cycloox	2003
[Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?]. Praxis, 2005, Nov-23, Volume: 94, Issue:47 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibi	2005
Celecoxib clinical profile. Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2000
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo	2001
Considerations for the safe prescribing and use of COX-2-specific inhibitors. The Medical journal of Australia, 2002, Apr-01, Volume: 176, Issue:7 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In	2002

Article	Year
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2018
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Celecoxib in the management of acute renal colic: a randomized controlled clinical trial. Urology, 2009, Volume: 74, Issue:5 Topics: Acute Disease; Adult; Celecoxib; Colic; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Huma	2009
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006

Article	Year
Renoprotective effect of celecoxib against gentamicin-induced nephrotoxicity through suppressing NFκB and caspase-3 signaling pathways in rats. Chemico-biological interactions, 2020, Jan-05, Volume: 315 Topics: Animals; Antioxidants; Apoptosis; Blood Urea Nitrogen; Caspase 3; Celecoxib; Creatinine; Cyclooxygen	2020
Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. European journal of pharmacology, 2020, Oct-05, Volume: 884 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Celecoxib; Cell Line; Cisplatin; Cytopr	2020
Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. Expert opinion on drug safety, 2019, Volume: 18, Issue:3 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Australia; Canada; Cardiovascular Diseases; Ce	2019
Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats. European journal of pharmacology, 2013, Nov-15, Volume: 720, Issue:1-3 Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cell Adhesi	2013
Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-β1/IL-2/COX-2/endothelin ET(B) receptor cascade. Toxicology and applied pharmacology, 2014, Mar-01, Volume: 275, Issue:2 Topics: Animals; Celecoxib; Creatinine; Cyclooxygenase 2; Cyclosporine; Fibrosis; Immunosuppressive Agents;	2014
Exacerbation of celecoxib-induced renal injury by concomitant administration of misoprostol in rats. PloS one, 2014, Volume: 9, Issue:2 Topics: Administration, Oral; Aldosterone; Analysis of Variance; Animals; Blood Pressure; Blood Urea Nitroge	2014
Hepatorenal protection in renal ischemia/reperfusion by celecoxib and pentoxifylline. The Journal of surgical research, 2016, Volume: 204, Issue:1 Topics: Animals; Biomarkers; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Kidney; Kid	2016
NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. Drug safety, 2008, Volume: 31, Issue:11 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflam	2008
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. Clinical therapeutics, 2003, Volume: 25, Issue:1 Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D	2003
Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding. The New England journal of medicine, 2003, Jun-12, Volume: 348, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Contraindications; Cyclooxyge	2003
Adverse Drug Events Involving COX-2 Inhibitors. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:9 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N	2003
Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney international, 2003, Volume: 64, Issue:6 Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diseas	2003
Hypertension associated with therapies to treat arthritis and pain. Hypertension (Dallas, Tex. : 1979), 2004, Volume: 44, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent	2004
Safety of short-term administration of celecoxib in decompensated cirrhosis. Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Kidney Diseases; Liver Cirrhosis; Naprox	2005
Celecoxib-induced nephrotoxicity in a renal transplant recipient. Pharmacotherapy, 2005, Volume: 25, Issue:5 Topics: Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Kidney Diseases; Kidney Transplantation; Ma	2005
Late-onset celecoxib-induced combined hepato-nephrotoxicity. British journal of clinical pharmacology, 2008, Volume: 66, Issue:1 Topics: Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase Inhibitors; Humans; Kidney Disease	2008
[Renal tolerance of selective inhibitors of cyclooxygenase type 2]. Presse medicale (Paris, France : 1983), 2001, Oct-20, Volume: 30, Issue:30 Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida	2001

celecoxib and Kidney Diseases